Luminex Corporation and ViroNovative Announce License Agreement for Human Metapneumovirus Rights
News Jul 15, 2008
Luminex Corporation and ViroNovative BV have announced that the companies have signed a licensing agreement that gives Luminex worldwide rights to use ViroNovative's human metapneumovirus (hMPV) intellectual property in the xTAG Respiratory Viral Panel (RVP).
Under the terms of the agreement, rights to ViroNovative's hMPV intellectual property will be extended to Luminex's distributors and end-user customers around the world.
"We are pleased to announce this license agreement in place with ViroNovative for human metapneumovirus," said Jeremy Bridge-Cook, vice president of Luminex Molecular Diagnostics.
"This virus is of increasing concern to healthcare providers worldwide. Having this license as part of our xTAG RVP assay is important to us as it allows our customers to use this cutting-edge test without the need to individually secure rights to this intellectual property."
Luminex's xTAG RVP received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on January 3, 2008. The test was cleared for the detection and identification of 12 viruses and viral subtypes that are together responsible for more than 85 percent of respiratory viral infections. xTAG RVP is the first multiplexed nucleic acid test for respiratory viruses cleared for in vitro diagnostic use by the FDA and is the first and only test cleared by FDA for the detection of hMPV.
"The Luminex platform has achieved remarkable market penetration, so we are delighted to have licensed Luminex Molecular Diagnostics rights to hMPV," said James Simon, chief operating officer of ViroNovative BV. "This agreement will help promote diagnosis of hMPV, an important virus that infects the respiratory tract and causes significant clinical impact in humans, especially in young children."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE